Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 141

1.

Targeting folate receptor alpha for cancer treatment.

Cheung A, Bax HJ, Josephs DH, Ilieva KM, Pellizzari G, Opzoomer J, Bloomfield J, Fittall M, Grigoriadis A, Figini M, Canevari S, Spicer JF, Tutt AN, Karagiannis SN.

Oncotarget. 2016 May 27. doi: 10.18632/oncotarget.9651. [Epub ahead of print] Review.

2.

Corrigendum: Frequent somatic transfer of mitochondrial DNA into the nuclear genome of human cancer cells.

Ju YS, Tubio JM, Mifsud W, Fu B, Davies HR, Ramakrishna M, Li Y, Yates L, Gundem G, Tarpey PS, Behjati S, Papaemmanuil E, Martin S, Fullam A, Gerstung M; ICGC Prostate Cancer Working Group; ICGC Bone Cancer Working Group; ICGC Breast Cancer Working Group, Nangalia J, Green AR, Caldas C, Borg Å, Tutt A, Lee MT, Van't Veer LJ, Tan BK, Aparicio S, Span PN, Martens JW, Knappskog S, Vincent-Salomon A, Børresen-Dale AL, Eyfjörd JE, Myklebost O, Flanagan AM, Foster C, Neal DE, Cooper C, Eeles R, Bova GS, Lakhani SR, Desmedt C, Thomas G, Richardson AL, Purdie CA, Thompson AM, McDermott U, Yang F, Nik-Zainal S, Campbell PJ, Stratton MR.

Genome Res. 2016 May;26(5):717.2. doi: 10.1101/gr.206557.116. No abstract available.

3.

Mutation Processes in 293-Based Clones Overexpressing the DNA Cytosine Deaminase APOBEC3B.

Akre MK, Starrett GJ, Quist JS, Temiz NA, Carpenter MA, Tutt AN, Grigoriadis A, Harris RS.

PLoS One. 2016 May 10;11(5):e0155391. doi: 10.1371/journal.pone.0155391. eCollection 2016.

4.

Landscape of somatic mutations in 560 breast cancer whole-genome sequences.

Nik-Zainal S, Davies H, Staaf J, Ramakrishna M, Glodzik D, Zou X, Martincorena I, Alexandrov LB, Martin S, Wedge DC, Van Loo P, Ju YS, Smid M, Brinkman AB, Morganella S, Aure MR, Lingjærde OC, Langerød A, Ringnér M, Ahn SM, Boyault S, Brock JE, Broeks A, Butler A, Desmedt C, Dirix L, Dronov S, Fatima A, Foekens JA, Gerstung M, Hooijer GK, Jang SJ, Jones DR, Kim HY, King TA, Krishnamurthy S, Lee HJ, Lee JY, Li Y, McLaren S, Menzies A, Mustonen V, O'Meara S, Pauporté I, Pivot X, Purdie CA, Raine K, Ramakrishnan K, Rodríguez-González FG, Romieu G, Sieuwerts AM, Simpson PT, Shepherd R, Stebbings L, Stefansson OA, Teague J, Tommasi S, Treilleux I, Van den Eynden GG, Vermeulen P, Vincent-Salomon A, Yates L, Caldas C, van't Veer L, Tutt A, Knappskog S, Tan BK, Jonkers J, Borg Å, Ueno NT, Sotiriou C, Viari A, Futreal PA, Campbell PJ, Span PN, Van Laere S, Lakhani SR, Eyfjord JE, Thompson AM, Birney E, Stunnenberg HG, van de Vijver MJ, Martens JW, Børresen-Dale AL, Richardson AL, Kong G, Thomas G, Stratton MR.

Nature. 2016 May 2;534(7605):47-54. doi: 10.1038/nature17676.

PMID:
27135926
5.

Development and Characterization of Monoclonal Antibodies Specific for Mouse and Human Fcγ Receptors.

Tutt AL, James S, Laversin SA, Tipton TR, Ashton-Key M, French RR, Hussain K, Vaughan AT, Dou L, Earley A, Dahal LN, Lu C, Dunscombe M, Chan HT, Penfold CA, Kim JH, Potter EA, Mockridge CI, Roghanian A, Oldham RJ, Cox KL, Lim SH, Teige I, Frendéus B, Glennie MJ, Beers SA, Cragg MS.

J Immunol. 2015 Dec 1;195(11):5503-16. doi: 10.4049/jimmunol.1402988. Epub 2015 Oct 28.

PMID:
26512139
6.

Anti-mouse FcγRIV antibody 9E9 also blocks FcγRIII in vivo.

Tipton TR, Mockridge CI, French RR, Tutt AL, Cragg MS, Beers SA.

Blood. 2015 Dec 10;126(24):2643-5. doi: 10.1182/blood-2015-09-671339. Epub 2015 Oct 22. No abstract available.

PMID:
26492935
7.

Frequent somatic transfer of mitochondrial DNA into the nuclear genome of human cancer cells.

Ju YS, Tubio JM, Mifsud W, Fu B, Davies HR, Ramakrishna M, Li Y, Yates L, Gundem G, Tarpey PS, Behjati S, Papaemmanuil E, Martin S, Fullam A, Gerstung M; ICGC Prostate Cancer Working Group; ICGC Bone Cancer Working Group; ICGC Breast Cancer Working Group, Nangalia J, Green AR, Caldas C, Borg Å, Tutt A, Lee MT, van't Veer LJ, Tan BK, Aparicio S, Span PN, Martens JW, Knappskog S, Vincent-Salomon A, Børresen-Dale AL, Eyfjörd JE, Flanagan AM, Foster C, Neal DE, Cooper C, Eeles R, Lakhani SR, Desmedt C, Thomas G, Richardson AL, Purdie CA, Thompson AM, McDermott U, Yang F, Nik-Zainal S, Campbell PJ, Stratton MR.

Genome Res. 2015 Jun;25(6):814-24. doi: 10.1101/gr.190470.115. Epub 2015 May 11. Erratum in: Genome Res. 2016 May;26(5):717.2.

8.

Mouse mammary stem cells express prognostic markers for triple-negative breast cancer.

Soady KJ, Kendrick H, Gao Q, Tutt A, Zvelebil M, Ordonez LD, Quist J, Tan DW, Isacke CM, Grigoriadis A, Smalley MJ.

Breast Cancer Res. 2015 Mar 4;17:31. doi: 10.1186/s13058-015-0539-6.

9.

New approaches for improving outcomes in breast cancer in Europe.

Di Leo A, Curigliano G, Diéras V, Malorni L, Sotiriou C, Swanton C, Thompson A, Tutt A, Piccart M.

Breast. 2015 Aug;24(4):321-30. doi: 10.1016/j.breast.2015.03.001. Epub 2015 Mar 31. Review.

10.

Robust BRCA1-like classification of copy number profiles of samples repeated across different datasets and platforms.

Schouten PC, Grigoriadis A, Kuilman T, Mirza H, Watkins JA, Cooke SA, van Dyk E, Severson TM, Rueda OM, Hoogstraat M, Verhagen CV, Natrajan R, Chin SF, Lips EH, Kruizinga J, Velds A, Nieuwland M, Kerkhoven RM, Krijgsman O, Vens C, Peeper D, Nederlof PM, Caldas C, Tutt AN, Wessels LF, Linn SC.

Mol Oncol. 2015 Aug;9(7):1274-86. doi: 10.1016/j.molonc.2015.03.002. Epub 2015 Mar 20.

11.

Genomic Complexity Profiling Reveals That HORMAD1 Overexpression Contributes to Homologous Recombination Deficiency in Triple-Negative Breast Cancers.

Watkins J, Weekes D, Shah V, Gazinska P, Joshi S, Sidhu B, Gillett C, Pinder S, Vanoli F, Jasin M, Mayrhofer M, Isaksson A, Cheang MC, Mirza H, Frankum J, Lord CJ, Ashworth A, Vinayak S, Ford JM, Telli ML, Grigoriadis A, Tutt AN.

Cancer Discov. 2015 May;5(5):488-505. doi: 10.1158/2159-8290.CD-14-1092. Epub 2015 Mar 13.

12.

Clinical and biological effects of an agonist anti-CD40 antibody: a Cancer Research UK phase I study.

Johnson P, Challis R, Chowdhury F, Gao Y, Harvey M, Geldart T, Kerr P, Chan C, Smith A, Steven N, Edwards C, Ashton-Key M, Hodges E, Tutt A, Ottensmeier C, Glennie M, Williams A.

Clin Cancer Res. 2015 Mar 15;21(6):1321-8. doi: 10.1158/1078-0432.CCR-14-2355. Epub 2015 Jan 14.

13.

Synthetic lethality and cancer therapy: lessons learned from the development of PARP inhibitors.

Lord CJ, Tutt AN, Ashworth A.

Annu Rev Med. 2015;66:455-70. doi: 10.1146/annurev-med-050913-022545. Epub 2014 Oct 17. Review.

PMID:
25341009
14.

The ErbB4 CYT2 variant protects EGFR from ligand-induced degradation to enhance cancer cell motility.

Kiuchi T, Ortiz-Zapater E, Monypenny J, Matthews DR, Nguyen LK, Barbeau J, Coban O, Lawler K, Burford B, Rolfe DJ, de Rinaldis E, Dafou D, Simpson MA, Woodman N, Pinder S, Gillett CE, Devauges V, Poland SP, Fruhwirth G, Marra P, Boersma YL, Plückthun A, Gullick WJ, Yarden Y, Santis G, Winn M, Kholodenko BN, Martin-Fernandez ML, Parker P, Tutt A, Ameer-Beg SM, Ng T.

Sci Signal. 2014 Aug 19;7(339):ra78. doi: 10.1126/scisignal.2005157.

PMID:
25140053
15.

Genomic scars as biomarkers of homologous recombination deficiency and drug response in breast and ovarian cancers.

Watkins JA, Irshad S, Grigoriadis A, Tutt AN.

Breast Cancer Res. 2014 Jun 3;16(3):211. doi: 10.1186/bcr3670. Review.

16.

IL15RA drives antagonistic mechanisms of cancer development and immune control in lymphocyte-enriched triple-negative breast cancers.

Marra P, Mathew S, Grigoriadis A, Wu Y, Kyle-Cezar F, Watkins J, Rashid M, De Rinaldis E, Hessey S, Gazinska P, Hayday A, Tutt A.

Cancer Res. 2014 Sep 1;74(17):4908-21. doi: 10.1158/0008-5472.CAN-14-0637. Epub 2014 Jun 30.

17.

Immunological visibility: posttranscriptional regulation of human NKG2D ligands by the EGF receptor pathway.

Vantourout P, Willcox C, Turner A, Swanson CM, Haque Y, Sobolev O, Grigoriadis A, Tutt A, Hayday A.

Sci Transl Med. 2014 Apr 9;6(231):231ra49. doi: 10.1126/scitranslmed.3007579.

18.

Changes in primary breast cancer heterogeneity may augment midtreatment MR imaging assessment of response to neoadjuvant chemotherapy.

Parikh J, Selmi M, Charles-Edwards G, Glendenning J, Ganeshan B, Verma H, Mansi J, Harries M, Tutt A, Goh V.

Radiology. 2014 Jul;272(1):100-12. doi: 10.1148/radiol.14130569. Epub 2014 Mar 19.

PMID:
24654970
19.

Assessment of microtubule-associated protein (MAP)-Tau expression as a predictive and prognostic marker in TACT; a trial assessing substitution of sequential docetaxel for FEC as adjuvant chemotherapy for early breast cancer.

Irshad S, Gillett C, Pinder SE, A'hern RP, Dowsett M, Ellis IO, Bartlett JM, Bliss JM, Hanby A, Johnston S, Barrett-Lee P, Ellis P, Tutt A.

Breast Cancer Res Treat. 2014 Apr;144(2):331-41. doi: 10.1007/s10549-014-2855-4. Epub 2014 Feb 12.

PMID:
24519386
20.

Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer.

Eccles SA, Aboagye EO, Ali S, Anderson AS, Armes J, Berditchevski F, Blaydes JP, Brennan K, Brown NJ, Bryant HE, Bundred NJ, Burchell JM, Campbell AM, Carroll JS, Clarke RB, Coles CE, Cook GJ, Cox A, Curtin NJ, Dekker LV, Silva Idos S, Duffy SW, Easton DF, Eccles DM, Edwards DR, Edwards J, Evans D, Fenlon DF, Flanagan JM, Foster C, Gallagher WM, Garcia-Closas M, Gee JM, Gescher AJ, Goh V, Groves AM, Harvey AJ, Harvie M, Hennessy BT, Hiscox S, Holen I, Howell SJ, Howell A, Hubbard G, Hulbert-Williams N, Hunter MS, Jasani B, Jones LJ, Key TJ, Kirwan CC, Kong A, Kunkler IH, Langdon SP, Leach MO, Mann DJ, Marshall JF, Martin L, Martin SG, Macdougall JE, Miles DW, Miller WR, Morris JR, Moss SM, Mullan P, Natrajan R, O'Connor JP, O'Connor R, Palmieri C, Pharoah PD, Rakha EA, Reed E, Robinson SP, Sahai E, Saxton JM, Schmid P, Smalley MJ, Speirs V, Stein R, Stingl J, Streuli CH, Tutt AN, Velikova G, Walker RA, Watson CJ, Williams KJ, Young LS, Thompson AM.

Breast Cancer Res. 2013 Oct 1;15(5):R92. doi: 10.1186/bcr3493. Review.

Items per page

Supplemental Content

Write to the Help Desk